News | March 14, 2026
Biogen unveils promising new data for Salanersen in kids with SMA
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Subscribe To Our Newsletter & Stay Updated
